Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer, Kidney Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth
of kidney cancer.
PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients
with metastatic kidney cancer.
OBJECTIVES:
Primary
- Determine the objective response rate in patients with metastatic renal clear cell
carcinoma treated with interferon alfa-1b.
Secondary
- Determine the toxicity of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence
of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
We found this trial at
1
site
Click here to add this to my saved trials
